165 related articles for article (PubMed ID: 38612799)
21. EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer.
Leal JL; Alexander M; Itchins M; Wright GM; Kao S; Hughes BGM; Pavlakis N; Clarke S; Gill AJ; Ainsworth H; Solomon B; John T
Clin Lung Cancer; 2021 Nov; 22(6):e859-e869. PubMed ID: 34127383
[TBL] [Abstract][Full Text] [Related]
22. A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
Sa H; Shi Y; Ding C; Ma K
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7729-7742. PubMed ID: 37004599
[TBL] [Abstract][Full Text] [Related]
23. A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancer.
van Veggel BAMH; van der Wekken AJ; Paats MS; Hendriks LEL; Hashemi SMS; Daletzakis A; van den Broek D; Bosch LJW; Monkhorst K; Smit EF; de Langen AJ
Cancer; 2024 Mar; 130(5):683-691. PubMed ID: 37905752
[TBL] [Abstract][Full Text] [Related]
24. First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
Okuma Y; Kubota K; Shimokawa M; Hashimoto K; Kawashima Y; Sakamoto T; Wakui H; Murakami S; Okishio K; Hayashihara K; Ohe Y;
JAMA Oncol; 2024 Jan; 10(1):43-51. PubMed ID: 37991747
[TBL] [Abstract][Full Text] [Related]
25. Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer.
Huang WS; Li F; Gong Y; Zhang Y; Youngsaye W; Xu Y; Zhu X; Greenfield MT; Kohlmann A; Taslimi PM; Toms A; Zech SG; Zhou T; Das B; Jang HG; Tugnait M; Ye YE; Gonzalvez F; Baker TE; Nadworny S; Ning Y; Wardwell SD; Zhang S; Gould AE; Hu Y; Lane W; Skene RJ; Zou H; Clackson T; Narasimhan NI; Rivera VM; Dalgarno DC; Shakespeare WC
Bioorg Med Chem Lett; 2023 Jan; 80():129084. PubMed ID: 36423823
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).
Cardona AF; Ruiz-Patiño A; Recondo G; Martín C; Raez L; Samtani S; Minata JN; Blaquier JB; Enrico D; Burotto M; Ordóñez-Reyes C; Chamorro DF; Garcia-Robledo JE; Corrales L; Zatarain-Barrón ZL; Más L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Mejía S; Jaller E; Vargas C; Carranza H; Otero J; Rodríguez J; Archila P; Bermudez M; Gamez T; Cordeiro de Lima V; Freitas H; Russo A; Polo C; Malapelle U; Perez DM; Rolfo C; Viola L; Rosell R; Arrieta O
Clin Lung Cancer; 2022 Sep; 23(6):522-531. PubMed ID: 35798634
[TBL] [Abstract][Full Text] [Related]
27. New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations.
David GM; Maria Del Pilar BC; Cristina MR
J Oncol Pharm Pract; 2023 Jun; 29(4):934-943. PubMed ID: 36916182
[TBL] [Abstract][Full Text] [Related]
28. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
29. [Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].
Yang X; Zhao J
Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):337-350. PubMed ID: 35599009
[TBL] [Abstract][Full Text] [Related]
30. Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion.
Hamada A; Suda K; Nishino M; Obata K; Oiki H; Fukami T; Fukuda S; Fujino T; Ohara S; Koga T; Chiba M; Shimoji M; Ito M; Takemoto T; Soh J; Tsutani Y; Mitsudomi T
J Thorac Oncol; 2024 Jan; 19(1):71-79. PubMed ID: 37666482
[TBL] [Abstract][Full Text] [Related]
31. An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations.
Park K; Kim JS; Kim JH; Kim YC; Kim HG; Cho EK; Jin JY; Kim M; Märten A; Kang JH
BMC Cancer; 2021 Jul; 21(1):802. PubMed ID: 34253172
[TBL] [Abstract][Full Text] [Related]
32. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).
Uryu K; Imamura Y; Shimoyama R; Mase T; Fujimura Y; Hayashi M; Ohtaki M; Otani K; Hibino M; Horiuchi S; Fukui T; Fukai R; Chihara Y; Iwase A; Yamada N; Tamura Y; Harada H; Shinozaki N; Tsuya A; Fukuoka M; Minami H
Jpn J Clin Oncol; 2024 Mar; 54(3):319-328. PubMed ID: 37997468
[TBL] [Abstract][Full Text] [Related]
33. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive
Yu HA; Paz-Ares LG; Yang JC; Lee KH; Garrido P; Park K; Kim JH; Lee DH; Mao H; Wijayawardana SR; Gao L; Hozak RR; Chao BH; Planchard D
Clin Cancer Res; 2021 Feb; 27(4):992-1002. PubMed ID: 33046516
[TBL] [Abstract][Full Text] [Related]
34. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
[TBL] [Abstract][Full Text] [Related]
35. FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
Duke ES; Stapleford L; Drezner N; Amatya AK; Mishra-Kalyani PS; Shen YL; Maxfield K; Zirkelbach JF; Bi Y; Liu J; Zhang X; Wang H; Yang Y; Zheng N; Reece K; Wearne E; Glen JJ; Ojofeitimi I; Scepura B; Nair A; Bikkavilli RK; Ghosh S; Philip R; Pazdur R; Beaver JA; Singh H; Donoghue M
Clin Cancer Res; 2023 Feb; 29(3):508-512. PubMed ID: 36112541
[TBL] [Abstract][Full Text] [Related]
36. EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study.
Araki T; Kanda S; Obara M; Agatsuma T; Kakizaki Y; Hama M; Yamamoto H; Takada M; Yamamoto M; Matsuo A; Kondo D; Komatsu M; Sonehara K; Tateishi K; Hanaoka M; Koizumi T
Respir Investig; 2024 Mar; 62(2):262-268. PubMed ID: 38245931
[TBL] [Abstract][Full Text] [Related]
37. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
Fang W; Huang Y; Hong S; Zhang Z; Wang M; Gan J; Wang W; Guo H; Wang K; Zhang L
BMC Cancer; 2019 Jun; 19(1):595. PubMed ID: 31208370
[TBL] [Abstract][Full Text] [Related]
38. Mobocertinib: A Potential Treatment for NSCLC with EGFR Exon 20 Insertions.
Pacheco JM
Cancer Discov; 2021 Jul; 11(7):1617-1619. PubMed ID: 34284994
[TBL] [Abstract][Full Text] [Related]
39. Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
de Marinis F; Laktionov KK; Poltoratskiy A; Egorova I; Hochmair M; Passaro A; Migliorino MR; Metro G; Gottfried M; Tsoi D; Ostoros G; Rizzato S; Mukhametshina GZ; Schumacher M; Novello S; Dziadziuszko R; Tang W; Clementi L; Cseh A; Kowalski D
Lung Cancer; 2021 Feb; 152():127-134. PubMed ID: 33387727
[TBL] [Abstract][Full Text] [Related]
40. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.
Cho BC; Felip E; Hayashi H; Thomas M; Lu S; Besse B; Sun T; Martinez M; Sethi SN; Shreeve SM; Spira AI
Future Oncol; 2022 Feb; 18(6):639-647. PubMed ID: 34911336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
